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Introduction 
Human mitochondrial respiratory chain complex I (CI) deficiency (MIM 252010) is the most 
common and challenging biochemical indicator of mitochondrial disease. Mitochondrial CI, or 
NADH-ubiquinone oxidoreductase, is a heteromeric structure composed of 45 subunits, seven 
encoded by mitochondrial DNA (mtDNA) genes and the remaining by nuclear genes.1,2 Several 
additional gene products contribute to its formation and activity. This genetic, structural and 
functional complexity can explain the extraordinary clinical heterogeneity of CI defects that range 
from mild muscle involvement to Leigh syndrome or fatal neonatal multiorgan disease.1 The 
nuclear gene NDUFA11 encodes one of the CI subunits, which is believed to have a role in 
assembly and/or stabilizing the membrane domain of CI.3 Only one report has been published of a 
disease caused by a mutation in this gene. The identified nucleotide change was at a splicing site 
and was inherited as a homozygous trait in affected individuals from three families of Israeli 
Bedouin origin. This mutation was associated with an early, often fatal, encephalocardiomyopathy 
phenotype and CI deficiency.4  
Here we describe a patient who is a compound heterozygote for two novel rare variants of 
NDUFA11 and affected by an adult onset neuromuscular phenotype, with a severe reduction of CI 
activity in muscle. 
 
Case Presentation 
The patient was a 72-year-old man with two healthy daughters and no family history of any 
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neuromuscular disease. At 65 years of age, he noted mild muscle weakness in his legs along with 
moderate leg stiffness.  Examination revealed saccadic eye movements and bilateral hearing loss. 
Mild, proximal leg weakness was present (Medical Research Council [MRC] scale: 4.5) along with 
a reduction in the muscle bulk of the thighs. Deep tendon reflexes were symmetrically reduced in 
the lower limbs.  No dysmetria or other cerebellar involvement was observed. No heart involvement 
was reported. Elevated creatine kinase (CK) levels (900 U/l) were detected.  
Needle electromyography examination revealed short duration, low amplitude motor unit potentials, 
absence of abnormal spontaneous activity, and an early recruitment pattern in the muscles of the 
arms and legs. Sensory and motor nerve conduction studies were normal.  A brain MRI showed 
diffuse white matter involvement due to cerebrovascular chronic lesions. 
Informed consent was obtained for biochemical and genetic studies. Histological and 
histochemical analyses of a muscle biopsy from the quadriceps showed diffuse mitochondrial 
alterations (Figure 1A-D). The biochemical assessment of the mitochondrial respiratory chain 
revealed an isolated and severe deficiency of CI (Figure 1E-F).  
The whole mtDNA sequence was normal. A genetic panel screening for nuclear genes 
encoding CI subunits and assembly factors was used and led to the identification of two 
heterozygous variants in NDUFA11 (c.317C>T, p.Thr106Ile and c.394G>C, p.Ala132Pro; Figure 
2A-B). Next generation sequencing revealed that the two variants were on different alleles (Figure 
2C). Notably, the two variants present in our proband were located in the C-terminal exon, present 
only in the alternative isoform 2 of NDUFAF11 (NM_001193375.1; NP_001180304.1) (Figure 2D). 
The variant c.317C>T was not reported in public SNP databases, while prediction programs gave 
contrasting results (Polyphen: benign; SIFT: deleterious) about the amino acid change p.Thr106Ile. 
However, the mutant nucleotide is located four positions from the intron 3-exon 4 junction and thus 
This article is protected by copyright. All rights reserved.
Adult myopathy due to NDUFA11 variant 
could affect the splicing process. In silico prediction analysis (Human Splicing Finder) suggested 
that the nucleotide change c.317C>T impairs splicing  (acceptor splice site: -9.22%), disrupting a 
splicing enhancer motif (site broken for enhancer motif SRp40 ). The variant c.394G>C is reported 
in dbSNPs as rs192066309 and has a frequency of 0.07% and 0.19% in the ExAC and gnomAD 
databases, respectively. The corresponding p.Ala132Pro missense change is predicted to be 
probably damaging by different bioinformatics tools (Polyphen2 and SIFT).  
Idebenone therapy (5 mg/kg per day) was started after the identification of the genetic cause and we 
observed a mild improvement in muscle strength as measured on the MRC scale and reported by the 
patient.  
No specimen was available from family members.  
 
Discussion 
This case represents the second report of biallelic mutations in NDUFA11. To date, only one 
mutation has been detected in this gene, associated with an extremely severe, early onset phenotype 
characterized by fatal infantile metabolic acidosis or severe encephalocardiomyopathy.4  
As previously mentioned  the two identified variants affect only isoform 2 of NDUFA11, and 
do not impair the production of isoform 1 (NM_175614).  This may explain the mild phenotype 
observed in the present patient. Moreover, we speculate that the observed tissue specificity of the 
clinical presentation may be due to a specific or predominant expression of isoform 2 in skeletal 
muscle tissue. Transcriptomic data in a public dataset (e.g. GTex) cannot confirm this hypothesis, 
because of the extremely low expression level of isoform 2 in all the reported tissues.  
This case further improves our understanding of the clinical disease phenotype associated 
with NDUFA11. We think that in the era of next generation sequencing it is extremely important to 
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describe all previously unreported variants and their corresponding clinical features to widen the 
clinical disease spectra and try to identify better genotype-phenotype correlations.  
Furthermore, CI-associated diseases could benefit from therapy with specific "CI bypass" 
agents, such as idebenone and menadione.5 The therapeutic effectiveness of idebenone in Leber 
hereditary optic atrophy, is well known.6 Although clear beneficial effects have been demonstrated 
in only a few other mitochondrial disorders,7 idebenone and coenzyme Q10 are currently used in 
clinical practice to treat mitochondrial dysfunction.  
Additional NDUFA11-mutant subjects are needed to confirm the possible role of this gene, 
or of its specific isoform 2, as a cause of mitochondrial myopathy and to better evaluate their 
potential responsiveness to idebenone treatment. 
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Figure 1: Histological, histochemical and biochemical studies on patient’s muscle biopsy 
A-B-C-D: Histological examination of the quadriceps muscle showed a ragged red fiber (RRF), 
numerous cytochrome c oxidase (COX) negative fibers along with scattered necrosis and a mild 
increase in connective tissue. Control samples for each staining are shownin the inserts. Scale bar: 
1cm:50µm 
A: Gomori trichrome staining (GT). The star (*) indicates a RRF, present in all panels. RRFs are 
expression of compensatory mitochondrial proliferation.  
B: COX staining  and  C: Succinate dehydrogenase staining (SDH) showing scattered COX 
negative and SDH hyperchromic fibres (*), expression of impairment of the respiratory complexes. 
D: COX/SDH double-staining highlights the presence of some COX-negative fibres, hyperchromic 
on SDH staining (*). 
E-F:  Biochemical analysis of mitochondrial respiratory chain complex activities in muscle from 
the proband. CI, CII, CIII, CIV: complex I, II, III, IV. All activities are normalized for citrate 
synthase (CS) activity. 
E: Values of specific activities for each complex are reported for the patient (*) and controls (grey 
boxes represent control ranges). 
F: Enzyme activities are expressed as percentages of the control mean. The dotted line indicates the 
lower values in the control range 
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Figure 2. Genetic findings 
A. Snapshot from IGV software of region containing the variants identified in the proband. 
NDUFA11 is on the (−) strand, thus IGV reports the reverse complementary nucleotides compared 
to cDNA.  
B. Electropherograms of the NDUFAF11 region containing the c.317C>T and c.394G>C variants.  
C. A detail of the panel A showing that each read contains either one or the other variant, thus 
indicating that they are in trans.  
D. Schematic structure of NDUFA11 transcripts: isoform1 (upper panel) and isoform 2 (lower 
panel). Blue boxes correspond to exons, white boxes to UnTranslated Regions. Black arrows 
indicate the position of the variants identified in the proband, affecting only isoform 2. The grey 
arrow indicates the position of the intronic mutation in NDUFA11 as previously reported4.  
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